Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial
详细信息 查看全文
- 作者：Wendy Waldman Zadeha ; wwaldman@broadlawns.org" class="auth_mail" title="E-mail the corresponding author ; Antonio Escartinb ; aescartin@santpau.cat" class="auth_mail" title="E-mail the corresponding author ; William Byrnesc ; Bill.Byrnes@ucb.com" class="auth_mail" title="E-mail the corresponding author ; Frank Tennigkeitd ; Frank.Tennigkeit@ucb.com" class="auth_mail" title="E-mail the corresponding author ; Simon Borghse ; simon.borghs@ucb.com" class="auth_mail" title="E-mail the corresponding author ; Ting Lic ; Ting.Li@ucb.com" class="auth_mail" title="E-mail the corresponding author ; Peter Dedekenf ; Peter.Dedeken@ucb.com" class="auth_mail" title="E-mail the corresponding author ; Marc De Backerf ; Marc.DeBacker@ucb.com" class="auth_mail" title="E-mail the corresponding author ; on behalf of the SP0954 Study Group1
- 关键词：Focal epilepsy ; Quality of life ; Seizure freedom ; Lacosamide
- 刊名：Seizure
- 出版年：2015
- 出版时间：September 2015
- 年：2015
- 卷：31
- 期：Complete
- 页码：72-79
- 全文大小：531 K
文摘
- •
Lacosamide 300–400 mg/day was efficacious as a first or later add-on for POS.
- •
37.5% of patients taking lacosamide as first add-on were seizure-free at 12 weeks.
- •
14.9% of patients taking lacosamide as later add-on were seizure-free at 12 weeks.
- •
Both patient groups reported improvements from Baseline in quality of life outcomes.
- •
Lacosamide was well tolerated, with a good tolerability profile as a first add-on.